{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,2]],"date-time":"2026-03-02T20:08:51Z","timestamp":1772482131316,"version":"3.50.1"},"reference-count":162,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2018,9,1]],"date-time":"2018-09-01T00:00:00Z","timestamp":1535760000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2018,9,1]],"date-time":"2018-09-01T00:00:00Z","timestamp":1535760000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/501100003593","name":"Conselho Nacional de Desenvolvimento Cient\u00edfico e Tecnol\u00f3gico","doi-asserted-by":"publisher","award":["306238\/2017-9"],"award-info":[{"award-number":["306238\/2017-9"]}],"id":[{"id":"10.13039\/501100003593","id-type":"DOI","asserted-by":"publisher"}]},{"name":"FAPERGS\/PPSUS","award":["1279-2551\/13-7"],"award-info":[{"award-number":["1279-2551\/13-7"]}]},{"name":"FAPERGS\/PRONEX","award":["16\/2551-0000499-4"],"award-info":[{"award-number":["16\/2551-0000499-4"]}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","jns-journal.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of the Neurological Sciences"],"published-print":{"date-parts":[[2018,9]]},"DOI":"10.1016\/j.jns.2018.06.020","type":"journal-article","created":{"date-parts":[[2018,6,25]],"date-time":"2018-06-25T18:53:29Z","timestamp":1529952809000},"page":"8-21","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":10,"special_numbering":"C","title":["Cholinergic and purinergic systems: A key to multiple sclerosis?"],"prefix":"10.1016","volume":"392","author":[{"given":"Carla Roberta Nunes","family":"Polachini","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Roselia Maria","family":"Spanevello","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Maria Rosa Chitolina","family":"Schetinger","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Vera Maria","family":"Morsch","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"1","key":"10.1016\/j.jns.2018.06.020_bb0005","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1016\/j.msard.2011.09.002","article-title":"Experimental in vivo and in vitro models of multiple sclerosis: EAE and beyond","volume":"1","author":"Kipp","year":"2012","journal-title":"Mult. Scler. Relat. Disord."},{"issue":"6","key":"10.1016\/j.jns.2018.06.020_bb0010","doi-asserted-by":"crossref","first-page":"1263","DOI":"10.1093\/cercor\/bhp193","article-title":"P2Y12 receptor protein in cortical gray matter lesions in multiple sclerosis","volume":"20","author":"Amadio","year":"2010","journal-title":"Cereb. Cortex"},{"issue":"1\u20132","key":"10.1016\/j.jns.2018.06.020_bb0015","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1016\/j.jneuroim.2006.11.026","article-title":"Neurodegeneration in autoimmune demyelination: recent mechanistic insights reveal novel therapeutic targets","volume":"184","author":"Aktas","year":"2007","journal-title":"J. Neuroimmunol."},{"key":"10.1016\/j.jns.2018.06.020_bb0020","series-title":"Neuroinflammation, Basic Neurochemistry: Molecular, Cellular and Medical Aspects","first-page":"610","author":"Bazan","year":"2012"},{"key":"10.1016\/j.jns.2018.06.020_bb0025","doi-asserted-by":"crossref","first-page":"216","DOI":"10.3389\/fncel.2017.00216","article-title":"Brain and peripheral atypical inflammatory mediators potentiate neuroinflammation and neurodegeneration","volume":"11","author":"Kempuraj","year":"2017","journal-title":"Front. Cell. Neurosci."},{"issue":"5","key":"10.1016\/j.jns.2018.06.020_bb0030","doi-asserted-by":"crossref","first-page":"693","DOI":"10.2174\/1381612822666161214153108","article-title":"Multiple sclerosis and neuroinflammation: the overview of current and prospective therapies","volume":"23","author":"Bjelobaba","year":"2017","journal-title":"Curr. Pharm. Des."},{"issue":"4","key":"10.1016\/j.jns.2018.06.020_bb0035","doi-asserted-by":"crossref","first-page":"406","DOI":"10.1016\/S1474-4422(14)70305-9","article-title":"Role of the innate and adaptive immune responses in the course of multiple sclerosis","volume":"14","author":"Hemmer","year":"2015","journal-title":"Lancet Neurol."},{"issue":"10076","key":"10.1016\/j.jns.2018.06.020_bb0040","doi-asserted-by":"crossref","first-page":"1357","DOI":"10.1016\/S0140-6736(16)31320-4","article-title":"Progressive multiple sclerosis: prospects for disease therapy, repair, and restoration of function","volume":"389","author":"Ontaneda","year":"2017","journal-title":"Lancet"},{"issue":"4\u20135","key":"10.1016\/j.jns.2018.06.020_bb0045","doi-asserted-by":"crossref","first-page":"518","DOI":"10.1016\/j.autrev.2014.01.012","article-title":"Revised diagnostic criteria of multiple sclerosis","volume":"13","author":"Milo","year":"2014","journal-title":"Autoimmun. Rev."},{"issue":"4","key":"10.1016\/j.jns.2018.06.020_bb0050","doi-asserted-by":"crossref","first-page":"654","DOI":"10.1111\/ene.12371","article-title":"Multiple sclerosis in children and adolescents: incidence and clinical picture-new insights from the nationwide German surveillance (2009\u20132011)","volume":"21","author":"Reinhardt","year":"2014","journal-title":"Eur. J. Neurol."},{"issue":"3","key":"10.1016\/j.jns.2018.06.020_bb0055","doi-asserted-by":"crossref","first-page":"134","DOI":"10.1038\/nrneurol.2015.14","article-title":"Multiple sclerosis-a quiet revolution","volume":"11","author":"Ransohoff","year":"2015","journal-title":"Nat. Rev. Neurol."},{"issue":"3","key":"10.1016\/j.jns.2018.06.020_bb0060","first-page":"B5212","article-title":"Gender differences in multiple sclerosis epidemiology and treatment response","volume":"63","author":"Magyari","year":"2016","journal-title":"Dan. Med. J."},{"issue":"4","key":"10.1016\/j.jns.2018.06.020_bb0065","doi-asserted-by":"crossref","first-page":"677","DOI":"10.1590\/1980-5918.029.004.ao03","article-title":"Assessment of patients with multiple sclerosis according to tests of the multiple sclerosis functional composite","volume":"29","author":"Figueiredo","year":"2016","journal-title":"Fisioter. Mov."},{"key":"10.1016\/j.jns.2018.06.020_bb0070","doi-asserted-by":"crossref","first-page":"460","DOI":"10.3389\/fncel.2015.00460","article-title":"Fatigue in multiple sclerosis: neural correlates and the role of non-invasive brain stimulation","volume":"9","author":"Chalah","year":"2015","journal-title":"Front. Cell. Neurosci."},{"issue":"3","key":"10.1016\/j.jns.2018.06.020_bb0075","doi-asserted-by":"crossref","first-page":"222","DOI":"10.1590\/1516-3180.2016.0200270117","article-title":"Characterization of the first symptoms of multiple sclerosis in a Brazilian center: cross-sectional study","volume":"135","author":"Cavenaghi","year":"2017","journal-title":"Sao Paulo Med. J."},{"issue":"3","key":"10.1016\/j.jns.2018.06.020_bb0080","doi-asserted-by":"crossref","first-page":"313","DOI":"10.1177\/1352458513496882","article-title":"Association between multiple sclerosis risk-associated SNPs and relapse and disability\u2014a prospective cohort study","volume":"20","author":"Lin","year":"2014","journal-title":"Mult. Scler."},{"issue":"11","key":"10.1016\/j.jns.2018.06.020_bb0085","doi-asserted-by":"crossref","first-page":"1204","DOI":"10.1136\/jnnp-2016-313722","article-title":"Role of genetic susceptibility variants in predicting clinical course in multiple sclerosis: a cohort study","volume":"87","author":"Pan","year":"2016","journal-title":"J. Neurol. Neurosurg. Psychiatry"},{"issue":"1","key":"10.1016\/j.jns.2018.06.020_bb0090","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1038\/nrneurol.2016.187","article-title":"Interactions between genetic, lifestyle and environmental risk factors for multiple sclerosis","volume":"13","author":"Olsson","year":"2017","journal-title":"Nat. Rev. Neurol."},{"issue":"3","key":"10.1016\/j.jns.2018.06.020_bb0095","first-page":"162","article-title":"Causal effect of genetic variants associated with body mass index on multiple sclerosis susceptibility","volume":"185","author":"Gianfrancesco","year":"2017","journal-title":"Am. J. Epidemiol."},{"issue":"15","key":"10.1016\/j.jns.2018.06.020_bb0100","doi-asserted-by":"crossref","first-page":"446","DOI":"10.1212\/WNL.0000000000002474","article-title":"Recommendations for observational studies of comorbidity in multiple sclerosis","volume":"86","author":"Marrie","year":"2016","journal-title":"Neurology"},{"key":"10.1016\/j.jns.2018.06.020_bb0105","doi-asserted-by":"crossref","first-page":"170","DOI":"10.1016\/j.ejmech.2012.10.055","article-title":"Synthesis of novel therapeutic agents for the treatment of multiple sclerosis: a brief overview","volume":"60","author":"Mulakayala","year":"2013","journal-title":"Eur. J. Med. Chem."},{"issue":"4","key":"10.1016\/j.jns.2018.06.020_bb0110","doi-asserted-by":"crossref","first-page":"406","DOI":"10.1177\/1352458510364992","article-title":"Clinico-pathological evidence that axonal loss underlies disability in progressive multiple sclerosis","volume":"16","author":"Tallantyre","year":"2010","journal-title":"Mult. Scler."},{"issue":"Pt 6","key":"10.1016\/j.jns.2018.06.020_bb0115","doi-asserted-by":"crossref","first-page":"1568","DOI":"10.1093\/brain\/awv086","article-title":"Evidence for early neurodegeneration in the cervical cord of patients with primary progressive multiple sclerosis","volume":"138","author":"Abdel-Aziz","year":"2015","journal-title":"Brain"},{"issue":"1","key":"10.1016\/j.jns.2018.06.020_bb0120","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1590\/S0004-282X2008000100004","article-title":"Immunomodulator therapy migration in relapsing remitting multiple sclerosis: a study of 152 cases","volume":"66","author":"Jordy","year":"2008","journal-title":"Arq. Neuropsiquiatr."},{"key":"10.1016\/j.jns.2018.06.020_bb0125","doi-asserted-by":"crossref","first-page":"134","DOI":"10.1016\/j.jaut.2014.01.022","article-title":"The diagnosis of multiple sclerosis and the various related demyelinating syndromes: a critical review","volume":"48-49","author":"Karussis","year":"2014","journal-title":"J. Autoimmun."},{"issue":"1","key":"10.1016\/j.jns.2018.06.020_bb0130","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1016\/j.euroneuro.2011.05.001","article-title":"The socioeconomic consequences of multiple sclerosis: a controlled national study","volume":"22","author":"Jennum","year":"2012","journal-title":"Eur. Neuropsychopharmacol."},{"issue":"1","key":"10.1016\/j.jns.2018.06.020_bb0135","doi-asserted-by":"crossref","first-page":"69","DOI":"10.3111\/13696998.2014.950420","article-title":"Treatment experience, burden and unmet needs (TRIBUNE) in MS study: results from Turkey","volume":"18","author":"Karabudak","year":"2015","journal-title":"J. Med. Econ."},{"issue":"2","key":"10.1016\/j.jns.2018.06.020_bb0140","doi-asserted-by":"crossref","first-page":"136","DOI":"10.1038\/nn.4475","article-title":"The role of peripheral immune cells in the CNS in steady state and disease","volume":"20","author":"Prinz","year":"2017","journal-title":"Nat. Neurosci."},{"issue":"2","key":"10.1016\/j.jns.2018.06.020_bb0145","doi-asserted-by":"crossref","first-page":"176","DOI":"10.1002\/msj.20245","article-title":"Therapeutics for multiple sclerosis symptoms","volume":"78","author":"Ben-Zacharia","year":"2011","journal-title":"Mt Sinai J. Med."},{"issue":"2","key":"10.1016\/j.jns.2018.06.020_bb0150","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1016\/S1474-4422(14)70256-X","article-title":"Pathological mechanisms in progressive multiple sclerosis","volume":"14","author":"Mahad","year":"2015","journal-title":"Lancet Neurol."},{"issue":"4","key":"10.1016\/j.jns.2018.06.020_bb0155","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1007\/s11910-016-0639-4","article-title":"The use of oral disease-modifying therapies in multiple sclerosis","volume":"16","author":"Kretzschmar","year":"2016","journal-title":"Curr. Neurol. Neurosci. Rep."},{"issue":"1","key":"10.1016\/j.jns.2018.06.020_bb0160","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1177\/1352458516664034","article-title":"The impact of drugs for multiple sclerosis on sleep","volume":"23","author":"Lanza","year":"2017","journal-title":"Mult. Scler."},{"key":"10.1016\/j.jns.2018.06.020_bb0165","article-title":"Interferons-beta versus glatiramer acetate for relapsing-remitting multiple sclerosis","volume":"11","author":"La Mantia","year":"2016","journal-title":"Cochrane Database Syst. Ver."},{"issue":"1","key":"10.1016\/j.jns.2018.06.020_bb0170","doi-asserted-by":"crossref","first-page":"15","DOI":"10.2174\/1871523014999150415130224","article-title":"Oral agents in multiple sclerosis","volume":"14","author":"Lorefice","year":"2015","journal-title":"Antiinflamm. Antiallergy Agents Med. Chem."},{"key":"10.1016\/j.jns.2018.06.020_bb0175","doi-asserted-by":"crossref","DOI":"10.1212\/NXI.0000000000000211","article-title":"Dimethyl fumarate treatment of relapsing-remitting multiple sclerosis influences B-cell subsets","volume":"3","author":"Lundy","year":"2016","journal-title":"Neurol. Neuroimmunol. Neuroinflamm."},{"issue":"2","key":"10.1016\/j.jns.2018.06.020_bb0180","doi-asserted-by":"crossref","DOI":"10.3390\/ijms18020271","article-title":"Dimethyl fumarate therapy significantly improves the responsiveness of T cells in multiple sclerosis patients for Immunoregulation by regulatory T cells","volume":"18","author":"Schl\u00f6der","year":"2017","journal-title":"Int. J. Mol. Sci."},{"issue":"62","key":"10.1016\/j.jns.2018.06.020_bb0185","first-page":"2","article-title":"Healthcare resource use and costs of multiple sclerosis patients in Germany before and during fampridine treatment","volume":"17","author":"Ziemssen","year":"2017","journal-title":"BMC Neurol."},{"key":"10.1016\/j.jns.2018.06.020_bb0190","article-title":"Fampridine response in MS patients with gait impairment in a real-world setting: need for new response criteria?","volume":"1","author":"Rodriguez-Leal","year":"2017","journal-title":"Mult. Scler."},{"issue":"2","key":"10.1016\/j.jns.2018.06.020_bb0195","doi-asserted-by":"crossref","first-page":"194","DOI":"10.1016\/S1474-4422(14)70231-5","article-title":"Treatment of progressive multiple sclerosis: what works, what does not, and what is needed","volume":"14","author":"Feinstein","year":"2015","journal-title":"Lancet Neurol."},{"issue":"5","key":"10.1016\/j.jns.2018.06.020_bb0200","doi-asserted-by":"crossref","first-page":"687","DOI":"10.1002\/jnr.23493","article-title":"Remyelination in multiple sclerosis: cellular mechanisms and novel therapeutic approaches","volume":"93","author":"Olsen","year":"2015","journal-title":"J. Neurosci. Res."},{"issue":"1","key":"10.1016\/j.jns.2018.06.020_bb0205","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1016\/j.clim.2011.03.004","article-title":"Immunopathogenesis of multiple sclerosis","volume":"142","author":"Comabella","year":"2012","journal-title":"Clin. Immunol."},{"key":"10.1016\/j.jns.2018.06.020_bb0210","doi-asserted-by":"crossref","first-page":"182","DOI":"10.1016\/j.ejphar.2015.03.042","article-title":"Animal models of multiple sclerosis","volume":"759","author":"Procaccini","year":"2015","journal-title":"Eur. J. Pharmacol."},{"key":"10.1016\/j.jns.2018.06.020_bb0215","doi-asserted-by":"crossref","first-page":"363","DOI":"10.1016\/j.biopha.2016.04.003","article-title":"Effects of chlorogenic acid on adenine nucleotides hydrolyzing enzyme activities and expression in platelets of rats experimentally demyelinated with ethidium bromide","volume":"81","author":"Leal","year":"2016","journal-title":"Biomed Pharmacother"},{"issue":"4","key":"10.1016\/j.jns.2018.06.020_bb0220","doi-asserted-by":"crossref","first-page":"378","DOI":"10.1016\/j.jnutbio.2014.11.006","article-title":"Anthocyanins suppress the secretion of proinflammatory mediators and oxidative stress, and restore ion pump activities in demyelination","volume":"26","author":"Carvalho","year":"2015","journal-title":"J. Nutr. Biochem."},{"issue":"25","key":"10.1016\/j.jns.2018.06.020_bb0225","doi-asserted-by":"crossref","first-page":"2947","DOI":"10.2174\/092986705774462833","article-title":"Anti-inflammatory immunotherapy for multiple sclerosis\/experimental autoimmune encephalomyelitis (EAE) disease","volume":"12","author":"Kanwar","year":"2005","journal-title":"Curr. Med. Chem."},{"key":"10.1016\/j.jns.2018.06.020_bb0230","doi-asserted-by":"crossref","DOI":"10.7717\/peerj.1189","article-title":"Cell death of spinal cord ED1(+) cells in a rat model of multiple sclerosis","volume":"3","author":"Trifunovi\u0107","year":"2015","journal-title":"PeerJ"},{"issue":"3","key":"10.1016\/j.jns.2018.06.020_bb0235","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1254\/jphs.12004FP","article-title":"The effect of ribavirin on reactive astrogliosis in experimental autoimmune encephalomyelitis","volume":"119","author":"Lavrnja","year":"2012","journal-title":"J. Pharmacol. Sci."},{"key":"10.1016\/j.jns.2018.06.020_bb0240","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.mcn.2016.02.003","article-title":"Early P2X7R-related astrogliosis in autoimmune encephalomyelitis","volume":"74","author":"Grygorowicz","year":"2016","journal-title":"Mol. Cell. Neurosci."},{"issue":"2702","key":"10.1016\/j.jns.2018.06.020_bb0245","first-page":"1","article-title":"Expression profiles of cholesterol metabolism-related genes are altered during development of experimental auto immune encephalomyelitis in the rat spinal cord","volume":"7","author":"Lavrnja","year":"2017","journal-title":"Sci. Rep."},{"key":"10.1016\/j.jns.2018.06.020_bb0250","doi-asserted-by":"crossref","first-page":"395","DOI":"10.1016\/j.neuroscience.2017.01.037","article-title":"Prolonged stimulation of a brainstem raphe region attenuates experimental autoimmune encephalomyelitis","volume":"346","author":"Madsen","year":"2017","journal-title":"Neuroscience"},{"issue":"6","key":"10.1016\/j.jns.2018.06.020_bb0255","doi-asserted-by":"crossref","first-page":"4723","DOI":"10.1007\/s12035-016-0014-0","article-title":"Autoimmune encephalomyelitis by inhibiting peripheral immune response and blood- brain barrier disruption","volume":"54","author":"Souza","year":"2017","journal-title":"Mol. Neurobiol."},{"issue":"5","key":"10.1016\/j.jns.2018.06.020_bb0260","doi-asserted-by":"crossref","first-page":"613","DOI":"10.1177\/1352458512458605","article-title":"Training in MS: influence of two different endurance training protocols (aquatic versus overland) on cytokine and neurotrophin concentrations during three week randomized controlled trial","volume":"19","author":"Bansi","year":"2013","journal-title":"Mult. Scler."},{"issue":"5","key":"10.1016\/j.jns.2018.06.020_bb0265","doi-asserted-by":"crossref","first-page":"696","DOI":"10.1309\/AJCP7UBK8IBVMVNR","article-title":"Analysis of proinflammatory and anti-inflammatory cytokine serum concentrations in patients with multiple sclerosis by using a multiplexed immunoassay","volume":"136","author":"Martins","year":"2011","journal-title":"Am. J. Clin. Pathol."},{"key":"10.1016\/j.jns.2018.06.020_bb0270","doi-asserted-by":"crossref","first-page":"266","DOI":"10.1016\/j.neuroscience.2014.01.048","article-title":"Alterations in the cholinesterase and adenosine deaminase activities and inflammation biomarker levels in patients with multiple sclerosis","volume":"266","author":"Polachini","year":"2014","journal-title":"Neuroscience"},{"issue":"12","key":"10.1016\/j.jns.2018.06.020_bb0275","doi-asserted-by":"crossref","DOI":"10.3390\/ijms17122009","article-title":"Dysregulated homeostasis of acetylcholine levels in immune cells of RR-multiple sclerosis patients","volume":"17","author":"Di Bari","year":"2016","journal-title":"Int. J. Mol. Sci."},{"issue":"4","key":"10.1016\/j.jns.2018.06.020_bb0280","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0061835","article-title":"Characteristic cerebrospinal fluid cytokine\/chemokine profiles in neuromyelitis optica, relapsing remitting or primary progressive multiple sclerosis","volume":"8","author":"Matsushita","year":"2013","journal-title":"PLoS One"},{"issue":"1\u20132","key":"10.1016\/j.jns.2018.06.020_bb0285","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1016\/j.jneuroim.2012.07.014","article-title":"The switch between relapse and remission in multiple sclerosis: continuous inflammatory response balanced by Th1 suppression and neurotrophic factors","volume":"252","author":"Gurevich","year":"2012","journal-title":"J. Neuroimmunol."},{"key":"10.1016\/j.jns.2018.06.020_bb0290","article-title":"An update on the role of matrix metalloproteinases in the pathogenesis of multiple sclerosis","volume":"13","author":"Boziki","year":"2017","journal-title":"Med. Chem."},{"issue":"9","key":"10.1016\/j.jns.2018.06.020_bb0295","doi-asserted-by":"crossref","first-page":"1376","DOI":"10.1016\/j.metabol.2016.05.018","article-title":"Role of metabolism in neurodegenerative disorders","volume":"65","author":"Procaccini","year":"2016","journal-title":"Metabolism"},{"issue":"2","key":"10.1016\/j.jns.2018.06.020_bb0300","doi-asserted-by":"crossref","first-page":"230","DOI":"10.1007\/s12640-015-9584-2","article-title":"Evaluation of delta-aminolevulinic dehydratase activity, oxidative stress biomarkers, and vitamin D levels in patients with multiple sclerosis","volume":"29","author":"Polachini","year":"2016","journal-title":"Neurotox. Res."},{"issue":"18\u201319","key":"10.1016\/j.jns.2018.06.020_bb0305","doi-asserted-by":"crossref","first-page":"2101","DOI":"10.1016\/S0024-3205(03)00068-7","article-title":"The lymphocytic cholinergic system and its biological function","volume":"72","author":"Kawashima","year":"2003","journal-title":"Life Sci."},{"issue":"43","key":"10.1016\/j.jns.2018.06.020_bb0310","first-page":"1","article-title":"Interaction of basal forebrain cholinergic neurons with the glucocorticoid system in stress regulation and cognitive impairment","volume":"7","author":"Paul","year":"2015","journal-title":"Front. Aging Neurosci."},{"issue":"30","key":"10.1016\/j.jns.2018.06.020_bb0315","doi-asserted-by":"crossref","first-page":"E6202","DOI":"10.1073\/pnas.1705491114","article-title":"Acetylcholine- producing NK cells attenuate CNS inflammation via modulation of infiltrating monocytes\/macrophages","volume":"114","author":"Jiang","year":"2017","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"issue":"1\u20133","key":"10.1016\/j.jns.2018.06.020_bb0320","doi-asserted-by":"crossref","first-page":"425","DOI":"10.1016\/j.cbi.2010.01.037","article-title":"Butyrylcholinesterase activity in multiple sclerosis neuropathology","volume":"187","author":"Darvesh","year":"2010","journal-title":"Chem. Biol. Interact."},{"issue":"5","key":"10.1016\/j.jns.2018.06.020_bb0325","doi-asserted-by":"crossref","first-page":"769","DOI":"10.1007\/s10072-012-1265-9","article-title":"Biological markers in cerebrospinal fluid for axonal impairment in multiple sclerosis: acetylcholinesterase activity cannot be considered a useful biomarker","volume":"34","author":"Antonelli","year":"2013","journal-title":"Neurol. Sci."},{"issue":"1\u20133","key":"10.1016\/j.jns.2018.06.020_bb0330","doi-asserted-by":"crossref","first-page":"92","DOI":"10.1016\/j.cbi.2008.04.046","article-title":"Cholinesterases in development and disease","volume":"175","author":"Anglister","year":"2008","journal-title":"Chem. Biol. Interact."},{"key":"10.1016\/j.jns.2018.06.020_bb0335","doi-asserted-by":"crossref","first-page":"409","DOI":"10.1016\/S1665-2681(19)30940-8","article-title":"Acetylcholinesterase and butyrylcholinesterase as markers of low-grade systemic inflammation","volume":"11","author":"Das","year":"2012","journal-title":"Ann. Hepatol."},{"key":"10.1016\/j.jns.2018.06.020_bb0340","doi-asserted-by":"crossref","first-page":"131","DOI":"10.4155\/fmc-2016-0213","article-title":"Probing the cholinergic system to understand neurodegenerative diseases","volume":"9","author":"Renard","year":"2017","journal-title":"Future Med. Chem."},{"issue":"2","key":"10.1016\/j.jns.2018.06.020_bb0345","doi-asserted-by":"crossref","first-page":"96","DOI":"10.1016\/j.tips.2014.12.002","article-title":"Nicotinic ACh receptors as therapeutic targets in CNS disorders","volume":"36","author":"Dineley","year":"2015","journal-title":"Trends Pharmacol. Sci."},{"issue":"4","key":"10.1016\/j.jns.2018.06.020_bb0350","doi-asserted-by":"crossref","first-page":"1025","DOI":"10.1124\/pr.113.008581","article-title":"Therapeutic potential of \u03b17 nicotinic acetylcholine receptors","volume":"67","author":"Bertrand","year":"2015","journal-title":"Pharmacol. Rev."},{"issue":"1","key":"10.1016\/j.jns.2018.06.020_bb0355","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.jphs.2017.05.002","article-title":"Physiological functions of the cholinergic system in immune cells","volume":"134","author":"Fujii","year":"2017","journal-title":"J. Pharmacol. Sci."},{"issue":"1","key":"10.1016\/j.jns.2018.06.020_bb0360","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1007\/s00726-011-1192-8","article-title":"Modulation of inflammatory pathways by the immune cholinergic system","volume":"45","author":"Nizri","year":"2013","journal-title":"Amino Acids"},{"issue":"1","key":"10.1016\/j.jns.2018.06.020_bb0365","doi-asserted-by":"crossref","first-page":"116","DOI":"10.1016\/j.neuron.2012.08.036","article-title":"Acetylcholine as a neuromodulator: cholinergic signaling shapes nervous system function and behavior","volume":"76","author":"Picciotto","year":"2012","journal-title":"Neuron"},{"issue":"21\u221222","key":"10.1016\/j.jns.2018.06.020_bb0370","doi-asserted-by":"crossref","first-page":"981","DOI":"10.1016\/j.lfs.2012.04.031","article-title":"Regulatory mechanisms of acetylcholine synthesis and release by T cells","volume":"91","author":"Fujii","year":"2012","journal-title":"Life Sci."},{"issue":"1","key":"10.1016\/j.jns.2018.06.020_bb0375","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1016\/j.intimp.2015.04.015","article-title":"Non-neuronal cholinergic system in regulation of immune function with a focus on \u03b17 nAChRs","volume":"29","author":"Kawashima","year":"2015","journal-title":"Int. Immunopharmacol."},{"key":"10.1016\/j.jns.2018.06.020_bb0380","first-page":"214","article-title":"Acetylcholinesterase and butyrylcholinesterase as possible markers of low-grade systemic inflammation","volume":"13","author":"Das","year":"2007","journal-title":"Med. Sci. Monit."},{"issue":"1","key":"10.1016\/j.jns.2018.06.020_bb0385","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1007\/s13539-012-0083-5","article-title":"Butyrylcholinesterase as a prognostic marker: a review of the literature","volume":"4","author":"Santarpia","year":"2013","journal-title":"J. Cachexia. Sarcopenia Muscle"},{"issue":"1","key":"10.1016\/j.jns.2018.06.020_bb0390","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1016\/j.nbd.2009.03.010","article-title":"The cholinergic anti-inflammatory system limits T cell infiltration into the neurodegenerative CNS, but cannot counteract complex CNS inflammation","volume":"35","author":"Nicolussi","year":"2009","journal-title":"Neurobiol. Dis."},{"issue":"2","key":"10.1016\/j.jns.2018.06.020_bb0395","doi-asserted-by":"crossref","first-page":"90","DOI":"10.2174\/1871524916666160829114533","article-title":"Role of the \u03b17 nicotinic acetylcholine receptor and RIC-3 in the cholinergic anti-inflammatory pathway","volume":"17","author":"Millet","year":"2017","journal-title":"Cent. Nerv. Syst. Agents Med. Chem."},{"issue":"5\u20136","key":"10.1016\/j.jns.2018.06.020_bb0400","doi-asserted-by":"crossref","first-page":"112","DOI":"10.1007\/s10354-010-0761-x","article-title":"The vagal immune reflex: a blessing from above","volume":"160","author":"van Westerloo","year":"2010","journal-title":"Wien. Med. Wochenschr."},{"issue":"1","key":"10.1016\/j.jns.2018.06.020_bb0405","doi-asserted-by":"crossref","first-page":"152","DOI":"10.1016\/j.intimp.2015.06.034","article-title":"Nicotinic receptor activation negatively modulates pro-inflammatory cytokine production in multiple sclerosis patients","volume":"29","author":"Reale","year":"2015","journal-title":"Int. Immunopharmacol."},{"issue":"10","key":"10.1016\/j.jns.2018.06.020_bb0410","doi-asserted-by":"crossref","first-page":"12656","DOI":"10.3390\/ijms131012656","article-title":"Relation between pro-inflammatory cytokines and acetylcholine levels in relapsing-remitting multiple sclerosis patients","volume":"13","author":"Reale","year":"2012","journal-title":"Int. J. Mol. Sci."},{"issue":"366","key":"10.1016\/j.jns.2018.06.020_bb0415","doi-asserted-by":"crossref","first-page":"ra24","DOI":"10.1126\/scisignal.aaa2147","article-title":"Control of IL-17 receptor signaling and tissue inflammation by the p38\u03b1-MKP-1 signaling axis in a mouse model of multiple sclerosis","volume":"8","author":"Huang","year":"2015","journal-title":"Sci. Signal."},{"issue":"3","key":"10.1016\/j.jns.2018.06.020_bb0420","doi-asserted-by":"crossref","first-page":"313","DOI":"10.1007\/s00401-011-0849-4","article-title":"Cholinergic imbalance in the multiple sclerosis hippocampus","volume":"122","author":"Kooi","year":"2011","journal-title":"Acta Neuropathol."},{"issue":"6","key":"10.1016\/j.jns.2018.06.020_bb0425","doi-asserted-by":"crossref","first-page":"710","DOI":"10.1016\/j.conb.2006.09.002","article-title":"The role of acetylcholine in learning and memory","volume":"16","author":"Hasselmo","year":"2006","journal-title":"Curr. Opin. Neurobiol."},{"issue":"4","key":"10.1016\/j.jns.2018.06.020_bb0430","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0122048","article-title":"Complement component C3 and butyrylcholinesterase activity are associated with neurodegeneration and clinical disability in multiple sclerosis","volume":"10","author":"Aeinehband","year":"2015","journal-title":"PLoS One"},{"issue":"167","key":"10.1016\/j.jns.2018.06.020_bb0435","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1016\/j.clim.2016.04.003","article-title":"Complement receptor 2 is increased in cerebrospinal fluid of multiple sclerosis patients and regulates C3 function","volume":"166-167","author":"Lindblom","year":"2016","journal-title":"Clin. Immunol."},{"key":"10.1016\/j.jns.2018.06.020_bb0440","doi-asserted-by":"crossref","unstructured":"Y. Li, S. Hai, Y. Zhou, B.R. Dong, Cholinesterase inhibitors for rarer dementias associated with neurological conditions, Cochrane Database Syst. Rev. (3) (2015) CD009444. https:\/\/doi.org\/10.1002\/14651858.CD009444.pub3.","DOI":"10.1002\/14651858.CD009444.pub3"},{"issue":"5","key":"10.1016\/j.jns.2018.06.020_bb0445","doi-asserted-by":"crossref","first-page":"540","DOI":"10.1016\/j.neuropharm.2005.10.013","article-title":"Anti-inflammatory properties of cholinergic up-regulation: a new role for acetylcholinesterase inhibitors","volume":"50","author":"Nizri","year":"2006","journal-title":"Neuropharmacology"},{"issue":"3","key":"10.1016\/j.jns.2018.06.020_bb0450","doi-asserted-by":"crossref","first-page":"340","DOI":"10.1007\/s10517-011-1137-y","article-title":"Effect of acetylcholine on mortality of mice from sepsis and proinflammatory cytokine production","volume":"150","author":"Zabrodskii","year":"2011","journal-title":"Bull. Exp. Biol. Med."},{"issue":"1","key":"10.1016\/j.jns.2018.06.020_bb0455","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1177\/1753425909104680","article-title":"Inhibitory role of cholinergic system mediated via alpha7 nicotinic acetylcholine receptor in LPS-induced neuro-inflammation","volume":"16","author":"Tyagi","year":"2010","journal-title":"Innate Immun."},{"issue":"5","key":"10.1016\/j.jns.2018.06.020_bb0460","doi-asserted-by":"crossref","first-page":"687","DOI":"10.1002\/glia.23101","article-title":"Cholinergic signaling in myelination","volume":"65","author":"Fields","year":"2017","journal-title":"Glia"},{"issue":"8","key":"10.1016\/j.jns.2018.06.020_bb0465","doi-asserted-by":"crossref","first-page":"1027","DOI":"10.1007\/s11064-006-9112-0","article-title":"Acetylcholinesterase activity in rats experimentally demyelinated with ethidium bromide and treated with interferon beta","volume":"31","author":"Mazzanti","year":"2006","journal-title":"Neurochem. Res."},{"issue":"4","key":"10.1016\/j.jns.2018.06.020_bb0470","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1016\/j.ijdevneu.2007.02.005","article-title":"Cyclosporine A inhibits acetylcholinesterase activity in rats experimentally demyelinated with ethidium bromide","volume":"25","author":"Mazzanti","year":"2007","journal-title":"Int. J. Dev. Neurosci."},{"issue":"1","key":"10.1016\/j.jns.2018.06.020_bb0475","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1016\/j.ijdevneu.2008.09.005","article-title":"Pre-treatment with ebselen and vitamin E modulate acetylcholinesterase activity: interaction with demyelinating agents","volume":"27","author":"Mazzanti","year":"2009","journal-title":"Int. J. Dev. Neurosci."},{"issue":"5","key":"10.1016\/j.jns.2018.06.020_bb0480","doi-asserted-by":"crossref","first-page":"796","DOI":"10.1111\/j.1471-4159.2010.07025.x","article-title":"Purinergic signalling at the plasma membrane: a multipurpose and multidirectional mode to deal with amyotrophic lateral sclerosis and multiple sclerosis","volume":"116","author":"Amadio","year":"2011","journal-title":"J. Neurochem."},{"issue":"5","key":"10.1016\/j.jns.2018.06.020_bb0485","doi-asserted-by":"crossref","first-page":"673","DOI":"10.1016\/j.bbamcr.2008.01.024","article-title":"Nucleotide- and nucleoside-converting ectoenzymes: important modulators of purinergic signalling cascade","volume":"1783","author":"Yegutkin","year":"2008","journal-title":"Biochim. Biophys. Acta"},{"key":"10.1016\/j.jns.2018.06.020_bb0490","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1016\/j.autneu.2015.04.014","article-title":"Impact of ectonucleotidases in autonomic nervous functions","volume":"191","author":"Cardoso","year":"2015","journal-title":"Auton. Neurosci."},{"issue":"4","key":"10.1016\/j.jns.2018.06.020_bb0495","doi-asserted-by":"crossref","first-page":"703","DOI":"10.1002\/med.21302","article-title":"Therapeutic potentials of ecto-nucleoside triphosphate diphosphohydro-lase triphosphate diphosphohydrolase, ecto-nucleotide pyrophosphatase\/ phosphodiesterase, ecto-5\u2032-nucleotidase, and alkaline phosphatase inhibitors","volume":"34","author":"Al-Rashida","year":"2014","journal-title":"Med. Res. Rev."},{"issue":"3","key":"10.1016\/j.jns.2018.06.020_bb0500","doi-asserted-by":"crossref","first-page":"257","DOI":"10.2174\/1871527315666160922104848","article-title":"Purinergic signalling and neurological diseases: an update","volume":"16","author":"Burnstock","year":"2017","journal-title":"CNS Neurol. Disord. Drug Targets"},{"issue":"148","key":"10.1016\/j.jns.2018.06.020_bb0505","article-title":"ATP as a multi-target danger signal in the brain","volume":"9","author":"Rodrigues","year":"2015","journal-title":"Front. Neurosci."},{"issue":"22","key":"10.1016\/j.jns.2018.06.020_bb0510","doi-asserted-by":"crossref","first-page":"3454","DOI":"10.1016\/j.febslet.2015.07.027","article-title":"CD73 and CD39 ectonucleotidases in T cell differentiation: beyond immunosuppression","volume":"589","author":"Bono","year":"2015","journal-title":"FEBS Lett."},{"issue":"5","key":"10.1016\/j.jns.2018.06.020_bb0515","doi-asserted-by":"crossref","first-page":"489","DOI":"10.1016\/S0028-3843(14)60318-2","article-title":"The role of ecto-purines in inflammation leading to demyelination - new means for therapies against multiple sclerosis","volume":"45","author":"Cie\u015blak","year":"2011","journal-title":"Neurol. Neurochir. Pol."},{"key":"10.1016\/j.jns.2018.06.020_bb0520","doi-asserted-by":"crossref","first-page":"414","DOI":"10.3389\/fimmu.2012.00414","article-title":"ATP release and purinergic signaling in NLRP3 inflammasome activation","volume":"3","author":"Gombault","year":"2013","journal-title":"Front. Immunol."},{"issue":"2","key":"10.1016\/j.jns.2018.06.020_bb0525","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1002\/biof.5520310205","article-title":"NTPDase and 5\u2032-nucleotidase activities in physiological and disease conditions: new perspectives for human health","volume":"31","author":"Schetinger","year":"2007","journal-title":"Biofactors"},{"issue":"2","key":"10.1016\/j.jns.2018.06.020_bb0530","doi-asserted-by":"crossref","first-page":"215","DOI":"10.2478\/jomb-2014-0025","article-title":"Brain injury alters ectonucleotidase activities and adenine nucleotide levels in rat serum","volume":"34","author":"Laketa","year":"2015","journal-title":"J. Med. Biochem."},{"issue":"3","key":"10.1016\/j.jns.2018.06.020_bb0535","doi-asserted-by":"crossref","first-page":"437","DOI":"10.1007\/s11302-012-9309-4","article-title":"Cellular function and molecular structure of ecto- nucleotidases","volume":"8","author":"Zimmermann","year":"2012","journal-title":"Purinergic Signal"},{"issue":"20","key":"10.1016\/j.jns.2018.06.020_bb0540","first-page":"1","article-title":"Recombinant ecto-5\u2032-nucleotidase (CD73) has long lasting antinociceptive effects that are dependent on adenosine A1 receptor activation","volume":"6","author":"Sowa","year":"2010","journal-title":"Mol. Pain"},{"issue":"2","key":"10.1016\/j.jns.2018.06.020_bb0545","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1111\/j.1748-1716.2010.02115.x","article-title":"Modulation and metamodulation of synapses by adenosine","volume":"199","author":"Ribeiro","year":"2010","journal-title":"Acta Physiol (Oxford)"},{"issue":"3","key":"10.1016\/j.jns.2018.06.020_bb0550","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1007\/s11302-013-9357-4","article-title":"Purinergic signaling in inflammatory cells: P2 receptor expression, functional effects, and modulation of inflammatory responses","volume":"9","author":"Jacob","year":"2013","journal-title":"Purinergic Signal"},{"issue":"12","key":"10.1016\/j.jns.2018.06.020_bb0555","doi-asserted-by":"crossref","first-page":"1919","DOI":"10.4103\/1673-5374.165300","article-title":"Purinergic signalling in neuroregeneration","volume":"10","author":"Burnstock","year":"2015","journal-title":"Neural Regen. Res."},{"issue":"1","key":"10.1016\/j.jns.2018.06.020_bb0560","doi-asserted-by":"crossref","first-page":"65","DOI":"10.55782\/ane-2011-1823","article-title":"Expression of purinergic P2X7 receptor in rat brain during the symptomatic phase of experimental autoimmune encephalomyelitis and after recovery of neurological deficits","volume":"71","author":"Grygorowicz","year":"2011","journal-title":"Acta Neurobiol. Exp. (Wars)"},{"issue":"6","key":"10.1016\/j.jns.2018.06.020_bb0565","doi-asserted-by":"crossref","first-page":"1019","DOI":"10.1111\/jnc.13724","article-title":"How does adenosine control neuronal dysfunction and neurodegeneration?","volume":"139","author":"Cunha","year":"2016","journal-title":"J. Neurochem."},{"issue":"5","key":"10.1016\/j.jns.2018.06.020_bb0570","doi-asserted-by":"crossref","first-page":"549","DOI":"10.1177\/1352458510364196","article-title":"Cerebral fluid ATP metabolites in multiple sclerosis","volume":"16","author":"Lazzarino","year":"2010","journal-title":"Mult. Scler."},{"key":"10.1016\/j.jns.2018.06.020_bb0575","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1155\/2011\/167156","article-title":"Serum metabolic profile in multiple sclerosis patients","volume":"2011","author":"Tavazzi","year":"2011","journal-title":"Mult. Scler. Int."},{"key":"10.1016\/j.jns.2018.06.020_bb0580","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1155\/2014\/759808","article-title":"Multiple sclerosis: evaluation of purine nucleotide metabolism in central nervoussystem in association with serum levels of selected fat-soluble antioxidants","volume":"2014","author":"Kura\u010dka","year":"2014","journal-title":"Mult. Scler. Int."},{"issue":"3\u20134","key":"10.1016\/j.jns.2018.06.020_bb0585","doi-asserted-by":"crossref","first-page":"210","DOI":"10.1016\/j.cca.2009.11.005","article-title":"The activity and expression of NTPDase is altered in lymphocytes of multiple sclerosis patients","volume":"411","author":"Spanevello","year":"2010","journal-title":"Clin. Chim. Acta"},{"issue":"1","key":"10.1016\/j.jns.2018.06.020_bb0590","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1007\/s00415-009-5258-4","article-title":"Activities of the enzymes that hydrolyze adenine nucleotides in platelets from multiple sclerosis patients","volume":"257","author":"Spanevello","year":"2010","journal-title":"J. Neurol."},{"issue":"4","key":"10.1016\/j.jns.2018.06.020_bb0595","doi-asserted-by":"crossref","first-page":"269","DOI":"10.21307\/ane-2017-026","article-title":"The physiology of blood platelets and changes of their biological activities in multiple sclerosis","volume":"76","author":"Wachowicz","year":"2016","journal-title":"Acta Neurobiol. Exp. (Wars)"},{"issue":"2","key":"10.1016\/j.jns.2018.06.020_bb0600","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1002\/glia.20110","article-title":"The cytokine IL-1beta transiently enhances P2X7 receptor expression and function in human astrocytes","volume":"49","author":"Narcisse","year":"2005","journal-title":"Glia"},{"issue":"35","key":"10.1016\/j.jns.2018.06.020_bb0605","doi-asserted-by":"crossref","first-page":"9525","DOI":"10.1523\/JNEUROSCI.0579-07.2007","article-title":"P2X(7) receptor blockade prevents ATP excitotoxicity in oligodendrocytes and ameliorates experimental autoimmune encephalomyelitis","volume":"27","author":"Matute","year":"2007","journal-title":"J. Neurosci."},{"issue":"422","key":"10.1016\/j.jns.2018.06.020_bb0610","first-page":"1","article-title":"Multiple sclerosis treatments affect monocyte-derived microvesicle production","volume":"8","author":"Blonda","year":"2017","journal-title":"Front. Neurol."},{"key":"10.1016\/j.jns.2018.06.020_bb0615","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1186\/1471-2377-6-12","article-title":"COX-2, CB2 and P2X7-immunoreactivities are increased in activated microglial cells\/ macrophages of multiple sclerosis and amyotrophic lateral sclerosis spinal cord","volume":"6","author":"Yiangou","year":"2006","journal-title":"BMC Neurol."},{"issue":"5","key":"10.1016\/j.jns.2018.06.020_bb0620","doi-asserted-by":"crossref","first-page":"468","DOI":"10.1016\/j.ceca.2011.08.002","article-title":"Gain-of-function of P2X7 receptor gene variants in multiple sclerosis","volume":"50","author":"Oyanguren-Desez","year":"2011","journal-title":"Cell Calcium"},{"key":"10.1016\/j.jns.2018.06.020_bb0625","doi-asserted-by":"crossref","unstructured":"B.J. Gu, J. Field, S. Dutertre, A. Ou, T.J. Kilpatrick, J. Lechner-Scott, R. Scott, R. Lea, B.V. Taylor, J. Stankovich, H. Butzkueven, M. Gresle, S.M. Laws, S. Petrou, S. Hoffjan, D.A. Akkad, C.A. Graham, S. Hawkins, A. Glaser, S.K. Bedri, J. Hillert, C. Matute, A. Antiguedad, ANZgene Consortium, J.S. Wiley, A rare P2X7 variant Arg307Gln with absent pore formation function protects against neuroinflammation in multiple sclerosis, Hum. Mol. Genet. 24 (19) (2015) 5644\u20135654. https:\/\/doi.org\/10.1093\/hmg\/ddv278.","DOI":"10.1093\/hmg\/ddv278"},{"issue":"6","key":"10.1016\/j.jns.2018.06.020_bb0630","first-page":"262","article-title":"NLRP3 inflammasome and its inhibitors: a review","author":"Shao","year":"2015","journal-title":"Front. Pharmacol."},{"issue":"1","key":"10.1016\/j.jns.2018.06.020_bb0635","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1016\/j.immuni.2017.06.020","article-title":"The P2X7 receptor in infection and inflammation","volume":"47","author":"Di Virgilio","year":"2017","journal-title":"Immunity"},{"issue":"3","key":"10.1016\/j.jns.2018.06.020_bb0640","doi-asserted-by":"crossref","first-page":"297","DOI":"10.1038\/s41419-018-0351-1","article-title":"Glutamate-induced and NMDA receptor-mediated neurodegeneration entails P2Y1 receptor activation","volume":"9","author":"Sim\u00f5es","year":"2018","journal-title":"Cell Death Dis."},{"issue":"2","key":"10.1016\/j.jns.2018.06.020_bb0645","doi-asserted-by":"crossref","first-page":"132","DOI":"10.1002\/glia.20160","article-title":"Metabotropic P2 receptor activation regulates oligodendrocyte progenitor migration and development","volume":"50","author":"Agresti","year":"2005","journal-title":"Glia"},{"issue":"2","key":"10.1016\/j.jns.2018.06.020_bb0650","doi-asserted-by":"crossref","first-page":"375","DOI":"10.1002\/glia.23097","article-title":"P2Y12 receptor is expressed on human microglia under physiological conditions throughout development and is sensitive to neuroinflammatory diseases","volume":"65","author":"Mildner","year":"2017","journal-title":"Glia"},{"key":"10.1016\/j.jns.2018.06.020_bb0655","doi-asserted-by":"crossref","first-page":"641","DOI":"10.1196\/annals.1423.067","article-title":"Mechanism of action of IFN-beta in the treatment of multiple sclerosis: a special reference to CD73 and adenosine","volume":"1110","author":"Airas","year":"2007","journal-title":"Ann. N. Y. Acad. Sci."},{"issue":"10","key":"10.1016\/j.jns.2018.06.020_bb0660","doi-asserted-by":"crossref","first-page":"2718","DOI":"10.1002\/eji.200838437","article-title":"IFN-beta regulates CD73 and adenosine expression at the blood-brain barrier","volume":"38","author":"Niemel\u00e4","year":"2008","journal-title":"Eur. J. Immunol."},{"issue":"8","key":"10.1016\/j.jns.2018.06.020_bb0665","doi-asserted-by":"crossref","first-page":"2206","DOI":"10.1002\/eji.201343314","article-title":"Multiple sclerosis lymphocytes upregulate A2A adenosine receptors that are antiinflammatory when stimulated","volume":"43","author":"Vincenzi","year":"2013","journal-title":"Eur. J. Immunol."},{"issue":"5","key":"10.1016\/j.jns.2018.06.020_bb0670","doi-asserted-by":"crossref","first-page":"650","DOI":"10.1002\/ana.1007","article-title":"Diminished adenosine A1 receptor expression on macrophages in brain and blood of patients with multiple sclerosis","volume":"49","author":"Johnston","year":"2001","journal-title":"Ann. Neurol."},{"issue":"4","key":"10.1016\/j.jns.2018.06.020_bb0675","doi-asserted-by":"crossref","first-page":"493","DOI":"10.1016\/S0006-2952(02)01548-4","article-title":"Use of the A2A adenosine receptor as a physiological immunosuppressor and to engineer inflammation in vivo","volume":"65","author":"Sitkovsky","year":"2003","journal-title":"Biochem. Pharmacol."},{"issue":"4","key":"10.1016\/j.jns.2018.06.020_bb0680","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1016\/j.neuint.2009.02.013","article-title":"Time-course changes in ectonucleotidase activities during experimental Autoimmune encephalomyelitis","volume":"55","author":"Lavrnja","year":"2009","journal-title":"Neurochem. Int."},{"issue":"4","key":"10.1016\/j.jns.2018.06.020_bb0685","doi-asserted-by":"crossref","first-page":"898","DOI":"10.1007\/s12031-014-0445-x","article-title":"Expression of a second ecto-5\u2032 nucleotidase variant besides the usual protein in symptomatic phase of experimental autoimmune encephalomyelitis","volume":"55","author":"Lavrnja","year":"2015","journal-title":"J. Mol. Neurosci."},{"issue":"4","key":"10.1016\/j.jns.2018.06.020_bb0690","doi-asserted-by":"crossref","first-page":"455","DOI":"10.1007\/s11064-006-9039-5","article-title":"Apyrase and 5\u2032-nucleotidase activities in synaptosomes from the cerebral cortex of rats experimentally demyelinated with ethidium bromide and treated with interferon-beta","volume":"31","author":"Spanevello","year":"2006","journal-title":"Neurochem. Res."},{"issue":"12","key":"10.1016\/j.jns.2018.06.020_bb0695","doi-asserted-by":"crossref","first-page":"1109","DOI":"10.1016\/j.lfs.2006.11.049","article-title":"Activities of enzymes that hydrolyze adenine nucleotides in platelets from rats experimentally demyelinated with ethidium bromide and treated with interferon-beta","volume":"80","author":"Spanevello","year":"2007","journal-title":"Life Sci."},{"issue":"9","key":"10.1016\/j.jns.2018.06.020_bb0700","doi-asserted-by":"crossref","first-page":"1192","DOI":"10.1016\/j.imbio.2013.04.004","article-title":"High interleukin-10 expression within the central nervous system may be important for initiation of recovery of dark Agouti rats from experimental autoimmune encephalomyelitis","volume":"218","author":"Bla\u017eevski","year":"2013","journal-title":"Immunobiology"},{"issue":"333","key":"10.1016\/j.jns.2018.06.020_bb0705","first-page":"1","article-title":"Down-regulation of NTPDase2 and ADP-sensitive P2 Purinoceptors correlate with severity of symptoms during experimental autoimmune encephalomyelitis","volume":"11","author":"Jakovljevic","year":"2017","journal-title":"Front. Cell. Neurosci."},{"key":"10.1016\/j.jns.2018.06.020_bb0710","doi-asserted-by":"crossref","first-page":"150","DOI":"10.1016\/j.neuroscience.2016.05.028","article-title":"Activation of the adenosine A2A receptor attenuates experimental autoimmune encephalomyelitis and is associated with increased intracellular calcium levels","volume":"330","author":"Liu","year":"2016","journal-title":"Neuroscience"},{"issue":"48","key":"10.1016\/j.jns.2018.06.020_bb0715","first-page":"1","article-title":"Dual roles of the adenosine A2a receptor in autoimmune neuroinflammation","volume":"13","author":"Ingwersen","year":"2016","journal-title":"J. Neuroinflammation"},{"issue":"1309","key":"10.1016\/j.jns.2018.06.020_bb0720","doi-asserted-by":"crossref","first-page":"116","DOI":"10.1016\/j.brainres.2009.10.054","article-title":"Chronic caffeine treatment attenuates experimental autoimmune encephalomyelitis induced by guinea pig spinal cord homogenates in Wistar rats","author":"Chen","year":"2010","journal-title":"Brain Res."},{"key":"10.1016\/j.jns.2018.06.020_bb0725","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1016\/j.neuropharm.2014.06.029","article-title":"Chronic caffeine treatment protects against experimental autoimmune encephalomyelitis in mice: therapeutic window and receptor subtype mechanism","volume":"86","author":"Wang","year":"2014","journal-title":"Neuropharmacology"},{"issue":"6","key":"10.1016\/j.jns.2018.06.020_bb0730","doi-asserted-by":"crossref","first-page":"1521","DOI":"10.1523\/JNEUROSCI.4271-03.2004","article-title":"A1 adenosine receptor upregulation and activation neuroinflammation and demyelination in a model of multiple sclerosis","volume":"24","author":"Tsutsui","year":"2004","journal-title":"J. Neurosci."},{"key":"10.1016\/j.jns.2018.06.020_bb0735","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1016\/j.autneu.2015.04.011","article-title":"Purinergic signaling in the immune system","volume":"191","author":"Di Virgilio","year":"2015","journal-title":"Auton. Neurosci."},{"issue":"2","key":"10.1016\/j.jns.2018.06.020_bb0740","doi-asserted-by":"crossref","first-page":"358","DOI":"10.1016\/j.pharmthera.2005.04.013","article-title":"Adenosine 5\u2032-triphosphate and adenosine as endogenous signaling molecules in immunity and inflammation","volume":"112","author":"Bours","year":"2006","journal-title":"Pharmacol. Ther."},{"issue":"7","key":"10.1016\/j.jns.2018.06.020_bb0745","doi-asserted-by":"crossref","first-page":"511","DOI":"10.1007\/s00011-016-0936-z","article-title":"The role of adenosine and adenosine receptors in the immunopathogenesis of multiple sclerosis","volume":"65","author":"Safarzadeh","year":"2016","journal-title":"Inflamm. Res."},{"issue":"5","key":"10.1016\/j.jns.2018.06.020_bb0750","doi-asserted-by":"crossref","first-page":"713","DOI":"10.1002\/dneu.20976","article-title":"Muscarinic receptor subtypes as potential targets to modulate oligodendrocyte progenitor survival, proliferation, and differentiation","volume":"72","author":"De Angelis","year":"2012","journal-title":"Dev. Neurobiol."},{"issue":"27","key":"10.1016\/j.jns.2018.06.020_bb0755","article-title":"Systematic review of pharmacological properties of the oligodendrocyte lineage","volume":"10","author":"Marinelli","year":"2016","journal-title":"Front. Cell. Neurosci."},{"issue":"5","key":"10.1016\/j.jns.2018.06.020_bb0760","doi-asserted-by":"crossref","first-page":"855","DOI":"10.1016\/S0896-6273(02)01067-X","article-title":"Adenosine: a neuron-glial transmitter promoting myelination in the CNS in response to action potentials","volume":"36","author":"Stevens","year":"2002","journal-title":"Neuron"},{"issue":"2","key":"10.1016\/j.jns.2018.06.020_bb0765","doi-asserted-by":"crossref","first-page":"622","DOI":"10.1111\/j.1471-4159.1987.tb04138.x","article-title":"ATP release from affinity-purified rat cholinergic nerve terminals","volume":"48","author":"Richardson","year":"1987","journal-title":"J. Neurochem."},{"issue":"Pt 1","key":"10.1016\/j.jns.2018.06.020_bb0770","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1111\/j.1469-7793.2000.t01-1-00143.x","article-title":"Co-release of ATP and ACh mediates hypoxic signalling at rat carotid body chemoreceptors","volume":"525","author":"Zhang","year":"2000","journal-title":"J. Physiol."},{"issue":"1","key":"10.1016\/j.jns.2018.06.020_bb0775","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1111\/j.1460-9568.1994.tb00245.x","article-title":"Purinergic modulation of the evoked release of [3H] acetylcholine from the hippocampus and cerebral cortex of the rat: role of the ectonucleotidases","volume":"6","author":"Cunha","year":"1994","journal-title":"Eur. J. Neurosci."},{"issue":"2","key":"10.1016\/j.jns.2018.06.020_bb0780","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1016\/S0006-8993(00)02679-2","article-title":"Facilitation by P(2) receptor activation of acetylcholine release from rat motor nerve terminals: interaction with presynaptic nicotinic receptors","volume":"877","author":"Salgado","year":"2000","journal-title":"Brain Res."},{"issue":"2","key":"10.1016\/j.jns.2018.06.020_bb0785","doi-asserted-by":"crossref","first-page":"1614","DOI":"10.1111\/j.1476-5381.1991.tb09836.x","article-title":"Inhibitory and excitatory effects of adenosine receptor agonists on evoked transmitter release from phrenic nerve ending of the rat","volume":"103","author":"Correia-De-S\u00e1","year":"1991","journal-title":"Br. J. Pharmacol."},{"issue":"1","key":"10.1016\/j.jns.2018.06.020_bb0790","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1046\/j.1471-4159.1994.63010207.x","article-title":"Excitatory and inhibitory effects of A1 and A2A adenosine receptor activation on the electrically evoked [3H]acetylcholine release from different areas of the rat hippocampus","volume":"63","author":"Cunha","year":"1994","journal-title":"J. Neurochem."},{"issue":"Pt 3","key":"10.1016\/j.jns.2018.06.020_bb0795","doi-asserted-by":"crossref","first-page":"671","DOI":"10.1111\/j.1469-7793.1998.671ba.x","article-title":"Functional interactions between nicotinic and P2X channels in short-term cultures of Guinea-pig submucosal neurons","volume":"513","author":"Barajas-L\u00f3pez","year":"1998","journal-title":"J. Physiol."},{"key":"10.1016\/j.jns.2018.06.020_bb0800","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1016\/j.neuropharm.2016.01.022","article-title":"Presynaptic P2X1-3 and \u03b13-containing nicotinic receptors assemble into functionally interacting ion channels in the rat hippocampus","volume":"105","author":"Rodrigues","year":"2016","journal-title":"Neuropharmacology"},{"issue":"7","key":"10.1016\/j.jns.2018.06.020_bb0805","doi-asserted-by":"crossref","first-page":"1600","DOI":"10.1111\/bph.12234","article-title":"Functional interaction between pre-synaptic \u03b16\u03b22-containing nicotinic and adenosine A2A receptors in the control of dopamine release in the rat striatum","volume":"169","author":"Gar\u00e7\u00e3o","year":"2013","journal-title":"Br. J. Pharmacol."},{"issue":"11","key":"10.1016\/j.jns.2018.06.020_bb0810","doi-asserted-by":"crossref","first-page":"1728","DOI":"10.1046\/j.1460-9568.2002.02020.x","article-title":"Modulation by adenosine of both muscarinic M1-facilitation and M2-inhibition of [3H]-acetylcholine release from the rat motor nerve terminals","volume":"15","author":"Oliveira","year":"2002","journal-title":"Eur. J. Neurosci."}],"container-title":["Journal of the Neurological Sciences"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0022510X18302703?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0022510X18302703?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,20]],"date-time":"2025-09-20T15:44:50Z","timestamp":1758383090000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0022510X18302703"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,9]]},"references-count":162,"alternative-id":["S0022510X18302703"],"URL":"https:\/\/doi.org\/10.1016\/j.jns.2018.06.020","relation":{},"ISSN":["0022-510X"],"issn-type":[{"value":"0022-510X","type":"print"}],"subject":[],"published":{"date-parts":[[2018,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Cholinergic and purinergic systems: A key to multiple sclerosis?","name":"articletitle","label":"Article Title"},{"value":"Journal of the Neurological Sciences","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jns.2018.06.020","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2018 Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}]}}